WO2004078777A3 - Dipeptidyl-peptidase protected proteins - Google Patents

Dipeptidyl-peptidase protected proteins Download PDF

Info

Publication number
WO2004078777A3
WO2004078777A3 PCT/US2004/006462 US2004006462W WO2004078777A3 WO 2004078777 A3 WO2004078777 A3 WO 2004078777A3 US 2004006462 W US2004006462 W US 2004006462W WO 2004078777 A3 WO2004078777 A3 WO 2004078777A3
Authority
WO
WIPO (PCT)
Prior art keywords
dipeptidyl
peptidase
peptides
protected proteins
polypeptides
Prior art date
Application number
PCT/US2004/006462
Other languages
French (fr)
Other versions
WO2004078777A2 (en
Inventor
Homayoun Sadeghi
Christopher P Prior
David J Ballance
Original Assignee
Biorexis Pharmaceutical Corp
Homayoun Sadeghi
Christopher P Prior
David J Ballance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,094 external-priority patent/US7176278B2/en
Application filed by Biorexis Pharmaceutical Corp, Homayoun Sadeghi, Christopher P Prior, David J Ballance filed Critical Biorexis Pharmaceutical Corp
Priority to EP04717362A priority Critical patent/EP1626981A4/en
Priority to US10/547,510 priority patent/US20070060512A1/en
Publication of WO2004078777A2 publication Critical patent/WO2004078777A2/en
Publication of WO2004078777A3 publication Critical patent/WO2004078777A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides modified therapeutic polypeptides or peptides partially or completely protected from DPP activity. The modified polypeptides or peptides comprise at least one additional amino acid at the amino terminus. The modified therapeutic polypeptides or peptides are useful in the treatment of diseases such as diabetes.
PCT/US2004/006462 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins WO2004078777A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04717362A EP1626981A4 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins
US10/547,510 US20070060512A1 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/378,094 2003-03-04
US10/378,094 US7176278B2 (en) 2001-08-30 2003-03-04 Modified transferrin fusion proteins
USPCT/US03/26818 2003-08-28
PCT/US2003/026818 WO2004020405A2 (en) 2002-08-30 2003-08-28 Modified transferrin fusion proteins

Publications (2)

Publication Number Publication Date
WO2004078777A2 WO2004078777A2 (en) 2004-09-16
WO2004078777A3 true WO2004078777A3 (en) 2006-02-16

Family

ID=32965093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006462 WO2004078777A2 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins

Country Status (2)

Country Link
EP (1) EP1626981A4 (en)
WO (1) WO2004078777A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
AU2006280004A1 (en) 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
CN102675221A (en) 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
ES2390286T3 (en) 2005-12-16 2012-11-08 Nektar Therapeutics GLP-1 polymer conjugates
CA2646598C (en) * 2006-03-21 2014-08-19 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2059818A2 (en) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
US8114632B2 (en) 2006-06-21 2012-02-14 Biocon Limited Method of producing biologically active polypeptide having insulinotropic activity
EP2046826B1 (en) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Exendin fusion proteins
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007331195A1 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
ES2628063T3 (en) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Glucagon analogs showing greater solubility in physiological pH buffers
MX2009008241A (en) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
ES2509883T3 (en) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
JP5753779B2 (en) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
CN102245624B (en) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 Insulin prodrug based on amide
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP6121323B2 (en) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Peptides of the glucagon superfamily exhibiting nuclear hormone receptor activity
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
KR102099462B1 (en) 2010-11-30 2020-04-10 제넨테크, 인크. Low affinity blood brain barrier receptor antibodies and uses therefor
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides with glucocorticoid receptor activity
CN104114183A (en) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 CTP-based insulin analogs for treatment of diabetes
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP6701208B2 (en) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Lipidated amide insulin prodrug
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
AU2016209968B2 (en) * 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
CN109053899B (en) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 Chimeric antigen receptor containing human transferrin antigen epitope sequence
SG11202009467YA (en) 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082898A2 (en) * 2002-03-28 2003-10-09 Prosidion Ltd. Novel analogues of glucose-dependent insulinotropic polypeptide
US20030199672A1 (en) * 1996-08-30 2003-10-23 Knudsen Liselotte Bjerre Derivatives of GLP-1 analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375393T1 (en) * 1998-01-30 2007-10-15 Asubio Pharma Co Ltd METHOD FOR PRODUCING A PEPTIDE USING AN AUXILIARY PEPTIDE
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
CN1363654A (en) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 Genetically engineered bacteria and process for preparing insulinotropic hormone secretion peptide GLP-1 (7-36)
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199672A1 (en) * 1996-08-30 2003-10-23 Knudsen Liselotte Bjerre Derivatives of GLP-1 analogs
WO2003082898A2 (en) * 2002-03-28 2003-10-09 Prosidion Ltd. Novel analogues of glucose-dependent insulinotropic polypeptide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEACON CF ET AL: "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.", DIABETOLOGIA., vol. 41, March 1998 (1998-03-01), pages 271 - 278, XP002202152 *
O'HARTE PM ET AL: "NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.", DIABETES., vol. 48, April 1999 (1999-04-01), pages 758 - 765, XP002993214 *
PEDERSEN J ET AL: "Removal of N-terminal polyhistidine tags from recombinant proteins using engineered aminopeptidases.", PROTEIN EXP PURIF., vol. 15, April 1999 (1999-04-01), pages 389 - 400, XP004441717 *
See also references of EP1626981A4 *
SIEGEL EG ET AL: "Biological activity of GLP-1-analogues with N-terminal modifications.", REGUL PEPT., vol. 79, February 1999 (1999-02-01), pages 93 - 102, XP002292371 *
ZHAO K. ET AL: "Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic.", BIOORG MED CHEM., vol. 11, January 2003 (2003-01-01), pages 207 - 215, XP002993215 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Also Published As

Publication number Publication date
EP1626981A4 (en) 2006-11-22
WO2004078777A2 (en) 2004-09-16
EP1626981A2 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2006017688A3 (en) Combination therapy using transferrin fusion proteins comprising glp-1
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2005003296A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
WO2011036443A3 (en) Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2011036445A3 (en) Polypeptides and uses thereof
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
EP2039367A4 (en) Prophylactic/therapeutic agent for neurodegenerative disease
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2005086825A3 (en) Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion
WO2006047728A3 (en) Bmp gene and fusion protein
WO2006000213A3 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2005079840A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
WO2005004894A3 (en) Methods for increasing cell and tissue viability
ATE485831T1 (en) TREATMENT OF NEURODEGENERATION
WO2004041859A3 (en) Peptide fragments of the harp factor inhibiting angiogenesis
WO2004111086A3 (en) Peptide analogues comprising at least one type of aminoacyl aza-$g(b)3 and the use thereof, in particular for therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004717362

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004717362

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007060512

Country of ref document: US

Ref document number: 10547510

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10547510

Country of ref document: US